This Medudy course is a video tutorial for physicians on the topic "MoonRISe-1: TAR-210 in non-muscle invasive bladder cancer".
Despite the availability of treatment options for patients with intermediate-risk non-muscle-invasive bladder cancer, recurrence rates remain high.
The Moonrise-1 trial is investigating TAR-210, an intravesical drug delivery system that enables the sustained release of erdafitinib directly into the bladder.
By providing localized treatment over 90 days, TAR-210 is expected to maximize therapeutic benefit while minimizing systemic side effects.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this course you will know
- the clinical background and relevance of the research question under investigation
- Study design and methodology of the publication to answer the research question
